Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome

Whorwell, Peter J.; Altringer, L. A.; Morel, Jorge G.; Bond, Yvonne; Charbonneau, Duane; O’Mahony, Liam; Kiely, Barry; Shanahan, Fergus; Quigley, Eamonn Martin

doi:10.1111/j.1572-0241.2006.00734.x

Cited by 694 publications

(622 citation statements)

References 38 publications

Supporting

Mentioning

561

Contrasting

Unclassified

Order By: Relevance

“…Moreover, it has been seen that, in vitro human dendritic cells stimulated with B. infantis selectively promoted the upregulation of FoxP3 expression in naïve lymphocytes [89]. Furthermore, B. infantis has been demonstrated to reduce symptom severity in patients with inflammatory bowel syndrome in two placebo-controlled human clinical studies [91,92].…”

Section: Use Of Probiotics For the Induction Of Regulatory T Cellsmentioning

confidence: 99%

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Dwivedi

Kemp

Laddha

et al. 2015

Autoimmunity Reviews

111

View full text Add to dashboard Cite

Vitiligo is a hypomelanotic autoimmune skin disease arising from a breakdown in immunological self-tolerance, which leads to aberrant immune responses against melanocytes.Regulatory T cells (Tregs) are crucial to the development of self-tolerance and so are major foci in the study of autoimmune pathogenesis of vitiligo. This review will summarise recent findings concerning the role of Tregs in the pathogenesis of vitiligo. In addition, as antigen-specific Tregs are a potential route for the reinstatement of immune tolerance, new strategies that expand or induce de novo generation of Tregs and which are currently being investigated as therapies for other autoimmune diseases, will be discussed. These approaches will highlight the opportunities for Treg cell-based therapeutics in vitiligo.4

show abstract

Section: Use Of Probiotics For the Induction Of Regulatory T Cellsmentioning

confidence: 99%

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Dwivedi

Kemp

Laddha

et al. 2015

Autoimmunity Reviews

111

View full text Add to dashboard Cite

show abstract

“…Several trials have been excluded from this list because of failure to compare with placebo (49) , re-analysis of old data (50) , unclear end points (51) or the use of multiple interventions (52) . Many early studies were small singlecentre trials (53)(54)(55)(56)(57) , although more recently a number of much larger multi-centre trials have been undertaken, reflecting the growing interest in the area (58)(59)(60)(61) .…”

Section: Probiotics In Irritable Bowel Syndrome: Clinical Trialsmentioning

confidence: 99%

Treating irritable bowel syndrome with probiotics: the evidence

2010

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a disorder of chronic abdominal pain, altered bowel habit and abdominal distension. It is the commonest cause of referral to gastroenterologists in the developed world and yet current therapeutic strategies are often unsatisfactory. There is now increasing evidence linking alterations in the gastrointestinal (GI) microbiota and IBS. Changes in faecal and mucosa-associated microbiota, post-infectious IBS, a link with small intestinal bacterial overgrowth and an up-regulation of the GI mucosal immune system all suggest a role for the GI microbiota in the pathogenesis of IBS. Given this evidence, therapeutic alteration of the GI microbiota by probiotic bacteria could be beneficial. The present paper establishes an aetiological framework for the use of probiotics in IBS and comprehensively reviews randomised placebo-controlled trials of probiotics in IBS using multiple electronic databases. It highlights safety concerns over the use of probiotics and attempts to establish guidelines for their use in IBS in both primary and secondary care.Probiotics: Irritable bowel syndrome: Small bowel intestinal overgrowth: Gastrointestinal microbiota

show abstract

“…Results from three randomized, controlled studies of B infantis 35624 indicated that some baseline symptoms of IBS improved after a 4-or 8-week course of daily B infantis 35624 therapy [75][76][77]. In a double-blind, placebo-controlled study, patients with IBS who were randomly assigned to receive B infantis 35624 capsules daily did not experience significant improvements in individual symptoms of IBS (i.e.…”

Section: Bifidobacterium Infantis 35624mentioning

confidence: 99%

“…In a randomized, double-blind, placebo-controlled, doseranging study of B infantis 35624 capsule administered once daily (range, 1 × 10 6 to 1 × 10 10 cells/dose) for 4 weeks, females with IBS (n = 362) who received B infantis 1 × 10 8 cells/dose (n = 90) experienced significant improvement from baseline in abdominal pain/discomfort after 4 weeks of treatment (P = 0.02) [76]. Further, patients who received B infantis 1 × 10 8 cells/dose experienced significant improvement from baseline in bloating/distension, sense of incomplete evacuation, flatulence, straining, and satisfaction with bowel habit compared with placebo [76].…”

Section: Bifidobacterium Infantis 35624mentioning

confidence: 99%

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Harris

Baffy

2017

Postgraduate Medicine

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS), which is characterized by recurrent abdominal pain and disordered bowel habits, is one of the most common functional bowel disorders. IBS is a substantial burden on both patient health-related quality of life and healthcare costs. Several pathophysiologic mechanisms have been postulated for the occurrence of IBS, including altered gastrointestinal motility, visceral hypersensitivity, changes in gut permeability, immune activation, gut-brain dysregulation, central nervous system dysfunction, and changes in the gut microbiota. Of note, both qualitative and quantitative differences have been observed in the gut microbiota of a population with IBS versus a healthy population. Because of the substantial interest in the gut microbiota and its role as a therapeutic target in IBS, this article provides an overview of specific interventions with the potential to modulate the gut microbiota in IBS, including elimination diets, prebiotics, probiotics, synbiotics, and nonsystemic antibiotics. Although probiotics and synbiotics are generally well tolerated, differences in the composition and concentration of different bacterial species and inclusion or exclusion of prebiotic components varies widely across studies and has prevented strong recommendations on their use in IBS. For nonsystemic antibiotics, rifaximin is indicated in the United States for the treatment of IBS with diarrhea in adults and has been shown to be efficacious and well tolerated in well-designed clinical trials. Overall, more consistent evidence is needed regarding the efficacy and safety of elimination diets, prebiotics, probiotics, and synbiotics for the treatment of patients with IBS. Furthermore, additional well-designed studies are needed that examine alterations in the gut microbiota that occur with these interventions and their potential associations with clinical symptoms of IBS. ARTICLE HISTORY

show abstract

Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome

Cited by 694 publications

References 38 publications

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Regulatory T cells in vitiligo: Implications for pathogenesis and therapeutics

Treating irritable bowel syndrome with probiotics: the evidence

Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome

Contact Info

Product

Resources

About